Lives saved by expanding HIV treatment availability in resource-limited settings: The example of haiti

Journal of Acquired Immune Deficiency Syndromes

Volumn 63, Issue 2, 2013, Pages

  Kimmel, April D ^a,b   Charles, MacArthur ^c   Deschamps, Marie Marcelle ^d   Severe, Patrice ^d   Edwards, Alison M ^b   Johnson, Warren D ^c   Fitzgerald, Daniel W ^c   Pape, Jean W ^c,d   Schackman, Bruce R ^b  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MASSACHUSETTS DEPARTMENT OF PUBLIC HEALTH   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d Centers Institute of Infectious Diseases and Reproductive Health   (Haïti)

Author keywords

Antiretroviral therapy; HIV AIDS; Mortality; Resourcelimited settings; Simulation

Indexed keywords

ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; DISEASE COURSE; HAITI; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MORTALITY; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; ACQUIRED IMMUNE DEFICIENCY SYNDROME; DEVELOPING COUNTRY; ECONOMICS; FORECASTING; HEALTH CARE FINANCING; HEALTH CARE PLANNING; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; PROBABILITY; TREATMENT OUTCOME;

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DEVELOPING COUNTRIES; DISEASE PROGRESSION; FORECASTING; HAITI; HEALTH RESOURCES; HEALTHCARE FINANCING; HUMANS; MARKOV CHAINS; TREATMENT OUTCOME;

MLCS; MLOWN;

EID: 84879761770     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3182918875     Document Type: Article

References (40)

1. World Health Organization, UNAIDS, UNICEF. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector. Progress report 2010. 2010. Available at: http://www.who.int/hiv/pub/2010progressreport/ summary-en.pdf. Accessed November 28, 2011.
2. Kates J, Wexler A, Lief E, et al. Financing the response to AIDS in low-and middle-income countries: international assistance from the G8, European Commission and other donor governments in 2010. 2011. Available at: http://www.kff.org/hivaids/upload/7347-07.pdf. Accessed November 8, 2011.
3. Moszynski P. Global Fund suspends new projects until 2014 because of lack of funding. BMJ. 2011;343:d7755.
4. World Health Organization. Global health sector strategy on HIV/AIDS 2011-2015. 2011. Available at: http://whqlibdoc.who.int/publications/2011/ 9789241501651-eng.pdf. Accessed November 9, 2011.
5. Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet. 2008;372:293-299.
6. Mills EJ, Bakanda C, Birungi J, et al. Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda. Ann Intern Med. 2011;155:209-216.
7. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2010 revision. 2010. Available at: http://whqlibdoc.who.int/publications/2010/ 9789241599764-eng.pdf. Accessed July 20, 2012.
8. Severe P, Juste MA, Ambroise A, et al. Early versus standard antiretro-viral therapy for HIV-infected adults in Haiti. N Engl J Med. 2010;363: 257-265.
9. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365:493-505.
10. Donnell D, Baeten JM, Kiarie J, et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet. 2010;375:2092-2098.
11. World Bank. World dataBank. 2009. Available at: databank.worldbank org. Accessed November 15, 2011.
12. Gaillard EM, Boulos LM, Andre Cayemittes MP, et al. Understanding the reasons for decline of HIV prevalence in Haiti. Sex Transm Infect. 2006;82(suppl 1):i14-i20.
13. UNAIDS. Country Fact Sheet: Haiti. 2011. Available at: http://www.unaids.org/en/dataanalysis/tools/aidsinfo/countryfactsheets/. Accessed October 14, 2011.
14. UNAIDS. AIDSinfo database. 2012. Available at: http://www.aidsinfoonline. org/. Accessed December 4, 2012.
15. The U.S. President's Emergency Plan for AIDS Relief (PEPFAR). Fiscal Year 2011: PEPFAR Operational Plan. December 2011. 2012. Available at: http://www.pepfar.gov/documents/organization/183974.pdf Accessed November 28, 2012.
16. The Global Fund to Fight AIDS Tuberculosis and Malaria. Haiti's Response to HIV/AIDS. 2012. Available at: http://portfolio. theglobalfund.org/en/Home/ Index. Accessed November 28, 2012.
17. Deschamps MM, Fitzgerald DW, Pape JW, et al. HIV infection in Haiti: natural history and disease progression. AIDS. 2000;14:2515-2521.
18. Fitzgerald DW, Severe P, Joseph P, et al. No effect of isoniazid prophylaxis for purified protein derivative-negative HIV-infected adults living in a country with endemic tuberculosis: results of a randomized trial. J Acquir Immune Defic Syndr. 2001;28:305-307.
19. Leger P, Charles M, Severe P, et al. 5-year survival of patients with AIDS receiving antiretroviral therapy in Haiti. N Engl J Med. 2009; 361:828-829.
20. Pape JW, Jean SS, Ho JL, et al. Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. Lancet. 1993;342:268-272.
21. Severe P, Leger P, Charles M, et al. Antiretroviral therapy in a thousand patients with AIDS in Haiti. N Engl J Med. 2005;353:2325-2334.
22. Charles M, Leger PD, Severe P, et al. Virologic, clinical and immunologic responses following failure of first-line antiretroviral therapy in Haiti. JInt AIDS Soc. 2012;15:1-7.
23. Cole SR, Hernan MA, Robins JM, et al. Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models. Am J Epidemiol. 2003;158: 687-694.
24. Losina E, Yazdanpanah Y, Deuffic-Burban S, et al. The independent effect of highly active antiretroviral therapy on severe opportunistic disease incidence and mortality in HIV-infected adults in Cote d' Ivoire. Antivir Ther. 2007;12:543-551.
25. Brinkh of MW, Pujades-Rodriguez M, Egger M. Mortality of patients lost to follow-up in antiretroviral treatment programmes in resource-limited settings: systematic review and meta-analysis. PLoS One. 2009;4:e5790.
26. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. MedDecis Making. 1993;13:322-338.
27. Siebert U, Alagoz O, Bayoumi AM, et al. State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-3. Med Decis Making. 2012;32:690-700.
28. Kimmel AD, Fitzgerald DW, Charles M, et al. Internal validation and calibration of a model to forecast HIV treatment demand and capacity in Haiti. Med Decis Making. 2012;32:E123.
29. Collett D. Modelling Survival Data in Medical Research. 2nd ed. Boca Raton, FL: Chapman & Hall/CRC; 2003.
30. Lindgren BW. Statistical Theory. 4th ed. New York, NY: Chapman & Hall; 1993.
31. Kimmel AD, Weinstein MC, Anglaret X, et al. Laboratory monitoring to guide switching antiretroviral therapy in resource-limited settings: clinical benefits and cost-effectiveness. J Acquir Immune Defic Syndr. 2010; 54:258-268.
32. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents in resource-limited settings: towards universal access. Recommendations for a public health approach. 2006 revision. 2006. Available at: http://www.who.int/hiv/pub/guidelines/artadultguidelines.pdf. Accessed February 23, 2011.
33. UNAIDS. Global Report: UNAIDS Report on the Global AIDS Epidemic 2010. 2010. Available at: http://www.unaids.org/globalreport/documents/20101123- GlobalReport-full-en.pdf. Accessed April 23, 2012.
34. Rosen S, Fox MP. Retention in HIV care between testing and treatment in sub-Saharan Africa: a systematic review. PLoS Med. 2011;8: e1001056.
35. Fox MP, Rosen S. Patient retention in antiretroviral therapy programs up to three years on treatment in sub-Saharan Africa, 2007-2009: systematic review. Trop Med Int Health. 2010;15(suppl 1):1-15.
36. Blanc FX, Sok T, Laureillard D, et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med. 2011;365:1471-1481.
37. Bangsberg DR, Perry S, Charlebois ED, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS. 2001; 15:1181-1183.
38. Abaasa AM, Todd J, Ekoru K, et al. Good adherence to HAART and improved survival in a community HIV/AIDS treatment and care programme: the experience of The AIDS Support Organization (TASO), Kampala, Uganda. BMC Health Serv Res. 2008;8:241.
39. Haiti Child Health Institute (CHI), Haitian Institute of Statistics and Informatics, Macro International I. Haiti Demographic and Health Survey 2005-2006. 2007. Accessed July 20, 2012, at http://www.measuredhs. com/pubs/pdf/FR192/FR192.pdf.
40. Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med. 1997;126:946-954.